Thursday, November 19, 2026
CN
  • About
  • Advertise
  • Careers
  • Contact
Money Compass
  • Home
  • Financial News
  • Investment News
  • Other News
    • Bursa News
    • Government News
    • Listing Companies News
    • Oversea Financial & Investment News
  • Interviews
    • Features Interviews
    • Corporate Interviews
  • Financial & Investment Articles
  • PR Newswire
  • Login
No Result
View All Result
Money Compass
Home PR Newswire

DNV supports FAMID Biomedical Technology in achieving IVDR certification for its Class C IVD in six months

Money Compass by Money Compass
November 19, 2026
in PR Newswire
0
DNV supports FAMID Biomedical Technology in achieving IVDR certification for its Class C IVD in six months
1
SHARES
100
VIEWS
Share on FacebookShare on Twitter

Certification supports European market access for a diagnostic test designed to aid the diagnosis of cervical precancerous lesions.

HOVIK, Norway, Nov. 19, 2026 /PRNewswire/ — DNV, an EU Notified Body for the In Vitro Diagnostic Medical Devices Regulation (IVDR), has issued an IVDR certificate to FAMID Biomedical Technology (Tianjin) Co., Ltd for its diagnostic test designed to support the early detection of cervical cancer.

Related posts

SCHLOSS JOHANNISBERG IS NAMED THE WORLD’S BEST VINEYARD 2026 AS THE LIST OF THE 50 BEST VINEYARDS IS REVEALED

SCHLOSS JOHANNISBERG IS NAMED THE WORLD’S BEST VINEYARD 2026 AS THE LIST OF THE 50 BEST VINEYARDS IS REVEALED

November 19, 2026
People’s Daily releases APEC ‘China Year’ promo: Why China?

People’s Daily releases APEC ‘China Year’ promo: Why China?

November 19, 2026

Certificate handover following IVDR certification of FAMID Biotech’s E7 Oncoprotein Rapid Test Kit.
Certificate handover following IVDR certification of FAMID Biotech’s E7 Oncoprotein Rapid Test Kit.

The certification was completed in just six months, following assessment of the manufacturer’s quality management system, clinical evidence and technical documentation.

FAMID Biomedical’s newly certified E7 Oncoprotein Rapid Test Kit, classified as a Class C in vitro diagnostic medical device under the IVDR, is designed as an aid in the diagnosis of cervical epithelial cell lesions through the detection of HPV E7 oncoprotein in cervical cell samples. The product is intended for both professional laboratory use and self-testing.

While every conformity assessment is different, the project demonstrates what can be achieved when a manufacturer enters the process well prepared.

Jim Miao, CEO of FAMID Biomedical Technology said:

“Bringing medical technologies to market requires not only strong technical capabilities, but also a certification partner who understands the importance of timely market access. Working with DNV has been a highly positive experience. Their professionalism, technical expertise and collaborative approach gave us confidence throughout the certification process and helped us progress efficiently towards bringing our technology to market. For our business, having a reliable and responsive partner is invaluable as we continue to develop our business and expand into new markets.”

Cecilie Gudesen Torp, Managing Director of Medical Technologies, Life Sciences at DNV commented:

“Achieving IVDR certification just six months after contract signing is a significant achievement and reflects both FAMID Biomedical Technology’s preparation and the expertise and close coordination of our teams throughout the assessment process. IVDR places significantly greater requirements on many diagnostic manufacturers, and this project demonstrates what can be achieved when strong preparation, specialist expertise and effective project management come together. Most importantly, the certification supports FAMID Biomedical Technology in bringing its diagnostic technology to the European market.”

DNV has built specialist IVDR competence and capacity across its global Medical Technologies organisation to support manufacturers navigating these requirements and is working with a growing portfolio of IVD manufacturers globally, combining local customer engagement with specialist regulatory and technical expertise across its international organization.

 

FAMID Biotech’s E7 Oncoprotein Rapid Test Kit and its testing components.
FAMID Biotech’s E7 Oncoprotein Rapid Test Kit and its testing components.

​ 

Previous Post

Reeracoen Vietnam Launches Benefits & Total Rewards Guide to Help Employers Prepare for 2027 Minimum Wage Rise and Tet

Next Post

People’s Daily releases APEC ‘China Year’ promo: Why China?

Next Post
People’s Daily releases APEC ‘China Year’ promo: Why China?

People's Daily releases APEC 'China Year' promo: Why China?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BROWSE BY CATEGORIES

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire

BROWSE BY TOPICS

2018 League Balinese Culture Bali United Budget Travel business Champions League Chopper Bike Doctor Terawan industrial Istana Negara Malaysia Market Stories National Exam net zero emissions targets 2025 Renewable energy Visit Bali

Recent News

  • SCHLOSS JOHANNISBERG IS NAMED THE WORLD’S BEST VINEYARD 2026 AS THE LIST OF THE 50 BEST VINEYARDS IS REVEALED
  • People’s Daily releases APEC ‘China Year’ promo: Why China?
  • Mastercard and Ant International Advance Trusted Agentic Commerce in Asia Pacific

Category

  • Blog
  • Bursa News
  • Corporate Interviews
  • Features Interviews
  • Financial & Investment Articles
  • Financial News
  • Government News
  • Investment News
  • Listing Companies News
  • Oversea Financial & Investment News
  • PR Newswire
  • About
  • Advertise
  • Careers
  • Contact

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Features Interviews
  • Government News
  • Financial News
  • Investment News
  • Listing Companies News
  • Corporate Interviews
  • Bursa News
  • Financial & Investment Articles
  • Oversea Financial & Investment News

Copyright © 2024 Money Compass Media (M) Sdn Bhd. All Rights Reserved